Inozyme Pharma to Present at Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY) announced that co-founder and CEO Axel Bolte will engage in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 11:10 AM ET. This event highlights the company’s commitment to advancing therapies for rare genetic conditions caused by abnormal mineralization, particularly focusing on ENPP1 and ABCC6 deficiencies. A replay of the discussion will be available for 30 days post-event on the Inozyme website.

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the Cowen 42^nd Annual Health Care Conference on Tuesday, March 8^th at 11:10 AM ET.

A replay of the fireside chat can be accessed from the Investor & News section of Inozyme’s website under events and will be available for up to 30 days following the event.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of Investor Relations
stefan.riley@inozyme.com        

Media:
SmithSolve
Matt Pera
973-886-9150
matt.pera@smithsolve.com

FAQ

What is Inozyme Pharma's focus area in their developments?

Inozyme Pharma focuses on developing novel therapeutics for diseases caused by abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.

When will Axel Bolte speak at the Cowen Health Care Conference?

Axel Bolte will participate in a fireside chat on March 8, 2022, at 11:10 AM ET.

How can I access the replay of the fireside chat?

The replay of the fireside chat can be accessed on Inozyme Pharma's website under the Investor & News section for up to 30 days after the event.

What clinical trial is Inozyme Pharma currently conducting?

Inozyme Pharma is currently conducting a Phase 1/2 clinical trial for its therapy INZ-701, aimed at treating ENPP1 Deficiency.

What is the ticker symbol for Inozyme Pharma?

The ticker symbol for Inozyme Pharma is INZY.